Alex Straumann1, Alfredo J Lucendo2, Stephan Miehlke3, Michael Vieth4, Christoph Schlag5, Luc Biedermann6, Cecilio Santander Vaquero7, Constanza Ciriza de Los Rios8, Christoph Schmoecker9, Ahmed Madisch10, Petr Hruz11, Jamal Hayat12, Ulrike von Arnim13, Albert Jan Bredenoord14, Stefan Schubert15, Ralph Mueller16, Roland Greinwald16, Alain Schoepfer17, Stephen Attwood18. 1. Swiss Eosinophilic Esophagitis Research Group, Olten, Switzerland; Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland. Electronic address: alex.straumann@hin.ch. 2. Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain; Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, Madrid, Spain; Instituto de Investigación Sanitaria Princesa, Madrid, Spain. 3. Center for Digestive Diseases, Internal Medicine Center Eppendorf, Hamburg, Germany; Center for Esophageal Disorders, University Hospital Hamburg-Eppendorf, Germany. 4. Institute for Pathology, Klinikum Bayreuth, Bayreuth, Germany. 5. II. Medizinische Klinik, Klinikum rechts der Isar, Technische Universität München, Munich, Germany. 6. Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland. 7. Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas, Madrid, Spain; Instituto de Investigación Sanitaria Princesa, Madrid, Spain; Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Madrid, Spain. 8. Department of Gastroenterology, Hospital Universitario 12 de Octubre, Madrid, Spain. 9. Department of Gastroenterology, Sana Klinikum Lichtenberg, Berlin, Germany. 10. Department of Gastroenterology, Clinical-Center Region Hannover Clinic Siloah, Hannover, Germany. 11. Department of Gastroenterology, University Hospital Basel, Basel, Switzerland. 12. Department of Gastroenterology, Saint George's University Hospitals National Health Service Trust, London, UK. 13. Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Magdeburg, Magdeburg, Germany. 14. Department of Gastroenterology and Hepatology, Academic Medical Center Amsterdam, Amsterdam, the Netherlands. 15. Private Practice, Berlin, Germany. 16. Department of Clinical Research and Development, Dr Falk Pharma GmbH, Freiburg, Germany. 17. Department of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland. 18. Department of Health Services Research, Durham University, Durham, UK.
Abstract
BACKGROUND & AIMS:Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder. Swallowed topical-acting corticosteroids are effective in bringing active EoE into remission. However, it is not clear whether these drugs are effective for long-term maintenance of remission. METHODS: We performed a double-blind trial to compare the efficacy and safety of 2 dosages of a budesonide orodispersible tablet (BOT) vs placebo in maintaining remission of EoE. Maintenance of remission was defined as absence of clinical and histologic relapse and no premature withdrawal for any reason. Two hundred and four adults with EoE in clinical and histologic remission, from 29 European study sites, were randomly assigned to groups given BOT 0.5 mg twice daily (n = 68), BOT 1.0 mg twice daily (n = 68), or placebo twice daily (n = 68) for up to 48 weeks. RESULTS: At end of treatment, 73.5% of patients receiving BOT 0.5 mg twice daily and 75% receiving BOT 1.0 mg twice daily were in persistent remission compared with 4.4% of patients in the placebo group (P < .001 for both comparisons of BOT with placebo). Median time to relapse in the placebo group was 87 days. The frequency of adverse events was similar in the BOT and placebo groups. Morning serum levels of cortisol were in the normal range at baseline and did not significantly change during treatment. Four patients receiving BOT developed asymptomatic, low serum levels of cortisol. Clinically manifested candidiasis was suspected in 16.2% of patients in the BOT 0.5 mg group and in 11.8% of patients in the BOT 1.0 mg group; all infections resolved with treatment. CONCLUSIONS: In a phase 3 trial, up to 48 weeks of treatment with BOT (0.5 mg or 1.0 mg twice daily) was superior to placebo in maintaining remission of EoE. Both dosages were equally effective and well tolerated. EudraCT number; 2014-001485-99; ClinicalTrials.gov number, NCT02434029.
RCT Entities:
BACKGROUND & AIMS:Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder. Swallowed topical-acting corticosteroids are effective in bringing active EoE into remission. However, it is not clear whether these drugs are effective for long-term maintenance of remission. METHODS: We performed a double-blind trial to compare the efficacy and safety of 2 dosages of a budesonide orodispersible tablet (BOT) vs placebo in maintaining remission of EoE. Maintenance of remission was defined as absence of clinical and histologic relapse and no premature withdrawal for any reason. Two hundred and four adults with EoE in clinical and histologic remission, from 29 European study sites, were randomly assigned to groups given BOT 0.5 mg twice daily (n = 68), BOT 1.0 mg twice daily (n = 68), or placebo twice daily (n = 68) for up to 48 weeks. RESULTS: At end of treatment, 73.5% of patients receiving BOT 0.5 mg twice daily and 75% receiving BOT 1.0 mg twice daily were in persistent remission compared with 4.4% of patients in the placebo group (P < .001 for both comparisons of BOT with placebo). Median time to relapse in the placebo group was 87 days. The frequency of adverse events was similar in the BOT and placebo groups. Morning serum levels of cortisol were in the normal range at baseline and did not significantly change during treatment. Four patients receiving BOT developed asymptomatic, low serum levels of cortisol. Clinically manifested candidiasis was suspected in 16.2% of patients in the BOT 0.5 mg group and in 11.8% of patients in the BOT 1.0 mg group; all infections resolved with treatment. CONCLUSIONS: In a phase 3 trial, up to 48 weeks of treatment with BOT (0.5 mg or 1.0 mg twice daily) was superior to placebo in maintaining remission of EoE. Both dosages were equally effective and well tolerated. EudraCT number; 2014-001485-99; ClinicalTrials.gov number, NCT02434029.
Authors: Tetsuo Shoda; Ting Wen; Julie M Caldwell; Netali Ben-Baruch Morgenstern; Garrett A Osswald; Mark Rochman; Lydia E Mack; Jennifer M Felton; J Pablo Abonia; Nicoleta C Arva; Dan Atkins; Peter A Bonis; Kelley E Capocelli; Margaret H Collins; Evan S Dellon; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; Ikuo Hirano; John Leung; Paul A Menard-Katcher; Vincent A Mukkada; Philip E Putnam; Amanda K Rudman Spergel; Jonathan M Spergel; Joshua B Wechsler; Guang-Yu Yang; Seema S Aceves; Glenn T Furuta; Marc E Rothenberg Journal: Gastroenterology Date: 2021-10-21 Impact factor: 22.682
Authors: Anjan Dhar; Hasan N Haboubi; Stephen E Attwood; Marcus K H Auth; Jason M Dunn; Rami Sweis; Danielle Morris; Jenny Epstein; Marco R Novelli; Hannah Hunter; Amanda Cordell; Sharon Hall; Jamal O Hayat; Kapil Kapur; Andrew Robert Moore; Carol Read; Sarmed S Sami; Paul J Turner; Nigel J Trudgill Journal: Gut Date: 2022-05-23 Impact factor: 31.793
Authors: Stephan Miehlke; Christoph Schlag; Alfredo J Lucendo; Luc Biedermann; Cecilio Santander Vaquero; Christoph Schmoecker; Jamal Hayat; Petr Hruz; Constanza Ciriza de Los Rios; Albert Jan Bredenoord; Michael Vieth; Alain Schoepfer; Stephen Attwood; Ralph Mueller; Sarah Burrack; Roland Greinwald; Alex Straumann Journal: United European Gastroenterol J Date: 2022-04 Impact factor: 4.623
Authors: Christopher Ma; Alain M Schoepfer; Evan S Dellon; Albert J Bredenoord; Mirna Chehade; Margaret H Collins; Brian G Feagan; Glenn T Furuta; Sandeep K Gupta; Ikuo Hirano; Vipul Jairath; David A Katzka; Rish K Pai; Marc E Rothenberg; Alex Straumann; Seema S Aceves; Jeffrey A Alexander; Nicoleta C Arva; Dan Atkins; Luc Biedermann; Carine Blanchard; Antonella Cianferoni; Constanza Ciriza de Los Rios; Frederic Clayton; Carla M Davis; Nicola de Bortoli; Jorge A Dias; Gary W Falk; Robert M Genta; Gisoo Ghaffari; Nirmala Gonsalves; Thomas Greuter; Russell Hopp; Karen S Hsu Blatman; Elizabeth T Jensen; Doug Johnston; Amir F Kagalwalla; Helen M Larsson; John Leung; Hubert Louis; Joanne C Masterson; Calies Menard-Katcher; Paul A Menard-Katcher; Fouad J Moawad; Amanda B Muir; Vincent A Mukkada; Roberto Penagini; Robert D Pesek; Kathryn Peterson; Philip E Putnam; Alberto Ravelli; Edoardo V Savarino; Christoph Schlag; Philipp Schreiner; Dagmar Simon; Thomas C Smyrk; Jonathan M Spergel; Tiffany H Taft; Ingrid Terreehorst; Tim Vanuytsel; Carina Venter; Mario C Vieira; Michael Vieth; Berber Vlieg-Boerstra; Ulrike von Arnim; Marjorie M Walker; Joshua B Wechsler; Philip Woodland; John T Woosley; Guang-Yu Yang; Noam Zevit; Ekaterina Safroneeva Journal: J Allergy Clin Immunol Date: 2021-07-06 Impact factor: 10.793